Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points

Toshihito Takatori, Norihito Shimono, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To prepare the sustained release suppositories, solid fats such as polyglycerol ester of fatty acids (PGEFs) or beeswax were utilized with a fatty suppository base, Witepsol H15. PGEFs such as decaglycerol heptabehenate (HB750) and hexaglycerol pentastearate (PS500), and beeswax have relatively high melting points. The addition of PGEFs or beeswax to Witepsol H15 increased the apparent viscosity of suppository bases at 37°C without any large change in the melting point of Witepsol H15. Moreover, the apparent viscosity of a mixed base with HB750, PS500 or beeswax at 37°C was significantly correlated with the amount of each solid fat in a mixed base. The release of acetaminophen (AAP), a model drug, from suppositories was delayed by HB750, PS500 or beeswax, and an excellent correlation was observed between the apparent viscosity of these mixed bases and Higuchi's rate constants in each mixed base suppository, suggesting that these solid fats could regulate the drug release from the mixed base suppositories by changing their viscosity. In the in vivo absorption study in rats, several suppositories made from Witepsol H15-HB750 or Witepsol H15-beeswax mixed bases prolonged the rectal absorption of AAP without reducing AUC. In conclusion, by using solid fats such as HB750 and beeswax with relatively high melting points, it is possible to control the rate of drug release from fatty base suppositories for maintaining the plasma concentration of drugs for longer time periods.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume278
Issue number2
DOIs
Publication statusPublished - Jul 8 2004

Fingerprint

Suppositories
Freezing
Fats
Viscosity
Acetaminophen
beeswax
Pharmaceutical Preparations
Area Under Curve
Esters
Fatty Acids
witepsol

Keywords

  • Beeswax
  • Controlled release
  • Fatty suppository
  • Polyglycerol ester of fatty acid
  • Solid fat with high melting point
  • Viscosity

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points. / Takatori, Toshihito; Shimono, Norihito; Higaki, Kazutaka; Kimura, Toshikiro.

In: International Journal of Pharmaceutics, Vol. 278, No. 2, 08.07.2004, p. 275-282.

Research output: Contribution to journalArticle

@article{3bfb6b626d984589ba48974c5733834c,
title = "Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points",
abstract = "To prepare the sustained release suppositories, solid fats such as polyglycerol ester of fatty acids (PGEFs) or beeswax were utilized with a fatty suppository base, Witepsol H15. PGEFs such as decaglycerol heptabehenate (HB750) and hexaglycerol pentastearate (PS500), and beeswax have relatively high melting points. The addition of PGEFs or beeswax to Witepsol H15 increased the apparent viscosity of suppository bases at 37°C without any large change in the melting point of Witepsol H15. Moreover, the apparent viscosity of a mixed base with HB750, PS500 or beeswax at 37°C was significantly correlated with the amount of each solid fat in a mixed base. The release of acetaminophen (AAP), a model drug, from suppositories was delayed by HB750, PS500 or beeswax, and an excellent correlation was observed between the apparent viscosity of these mixed bases and Higuchi's rate constants in each mixed base suppository, suggesting that these solid fats could regulate the drug release from the mixed base suppositories by changing their viscosity. In the in vivo absorption study in rats, several suppositories made from Witepsol H15-HB750 or Witepsol H15-beeswax mixed bases prolonged the rectal absorption of AAP without reducing AUC. In conclusion, by using solid fats such as HB750 and beeswax with relatively high melting points, it is possible to control the rate of drug release from fatty base suppositories for maintaining the plasma concentration of drugs for longer time periods.",
keywords = "Beeswax, Controlled release, Fatty suppository, Polyglycerol ester of fatty acid, Solid fat with high melting point, Viscosity",
author = "Toshihito Takatori and Norihito Shimono and Kazutaka Higaki and Toshikiro Kimura",
year = "2004",
month = "7",
day = "8",
doi = "10.1016/j.ijpharm.2004.03.030",
language = "English",
volume = "278",
pages = "275--282",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points

AU - Takatori, Toshihito

AU - Shimono, Norihito

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2004/7/8

Y1 - 2004/7/8

N2 - To prepare the sustained release suppositories, solid fats such as polyglycerol ester of fatty acids (PGEFs) or beeswax were utilized with a fatty suppository base, Witepsol H15. PGEFs such as decaglycerol heptabehenate (HB750) and hexaglycerol pentastearate (PS500), and beeswax have relatively high melting points. The addition of PGEFs or beeswax to Witepsol H15 increased the apparent viscosity of suppository bases at 37°C without any large change in the melting point of Witepsol H15. Moreover, the apparent viscosity of a mixed base with HB750, PS500 or beeswax at 37°C was significantly correlated with the amount of each solid fat in a mixed base. The release of acetaminophen (AAP), a model drug, from suppositories was delayed by HB750, PS500 or beeswax, and an excellent correlation was observed between the apparent viscosity of these mixed bases and Higuchi's rate constants in each mixed base suppository, suggesting that these solid fats could regulate the drug release from the mixed base suppositories by changing their viscosity. In the in vivo absorption study in rats, several suppositories made from Witepsol H15-HB750 or Witepsol H15-beeswax mixed bases prolonged the rectal absorption of AAP without reducing AUC. In conclusion, by using solid fats such as HB750 and beeswax with relatively high melting points, it is possible to control the rate of drug release from fatty base suppositories for maintaining the plasma concentration of drugs for longer time periods.

AB - To prepare the sustained release suppositories, solid fats such as polyglycerol ester of fatty acids (PGEFs) or beeswax were utilized with a fatty suppository base, Witepsol H15. PGEFs such as decaglycerol heptabehenate (HB750) and hexaglycerol pentastearate (PS500), and beeswax have relatively high melting points. The addition of PGEFs or beeswax to Witepsol H15 increased the apparent viscosity of suppository bases at 37°C without any large change in the melting point of Witepsol H15. Moreover, the apparent viscosity of a mixed base with HB750, PS500 or beeswax at 37°C was significantly correlated with the amount of each solid fat in a mixed base. The release of acetaminophen (AAP), a model drug, from suppositories was delayed by HB750, PS500 or beeswax, and an excellent correlation was observed between the apparent viscosity of these mixed bases and Higuchi's rate constants in each mixed base suppository, suggesting that these solid fats could regulate the drug release from the mixed base suppositories by changing their viscosity. In the in vivo absorption study in rats, several suppositories made from Witepsol H15-HB750 or Witepsol H15-beeswax mixed bases prolonged the rectal absorption of AAP without reducing AUC. In conclusion, by using solid fats such as HB750 and beeswax with relatively high melting points, it is possible to control the rate of drug release from fatty base suppositories for maintaining the plasma concentration of drugs for longer time periods.

KW - Beeswax

KW - Controlled release

KW - Fatty suppository

KW - Polyglycerol ester of fatty acid

KW - Solid fat with high melting point

KW - Viscosity

UR - http://www.scopus.com/inward/record.url?scp=2942613003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942613003&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2004.03.030

DO - 10.1016/j.ijpharm.2004.03.030

M3 - Article

C2 - 15196632

AN - SCOPUS:2942613003

VL - 278

SP - 275

EP - 282

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 2

ER -